NSPR Overview

Company Announcement: InspireMD, Inc. will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference on December 3rd, 2025, at 12:30 pm ET.

Webcast Availability: A live audio webcast and replay of the discussion will be accessible on the company's website under the "Investor Calendar" section.

Product Focus: InspireMD is focused on its CGuard® Prime carotid stent system, which aims to prevent strokes using its proprietary MicroNet™ mesh technology.

Investor Information: InspireMD's common stock is traded on Nasdaq under the ticker symbol NSPR, and the company provides important updates for investors on its website.

Earnings Report: InspireMD, Inc. reported a third-quarter loss of $12.71 million, or $0.17 per share, which is an increase from last year's loss of $7.89 million, or $0.16 per share.

Analyst Expectations: The company's loss was better than analysts' expectations, who had predicted a loss of $0.19 per share.

Revenue Growth: Revenue for the quarter rose by 39.2% to $2.52 million, up from $1.81 million in the same period last year.

Earnings Summary: Key figures include a loss of $12.71 million, an EPS of -$0.17, and revenue of $2.52 million compared to last year's figures.

Appointment of Chief Medical Officer: InspireMD, Inc. has appointed Peter Soukas as Chief Medical Officer to enhance its carotid intervention tools, specifically the CGuard Prime carotid stent system.

Expertise and Experience: Soukas is a highly experienced vascular intervention specialist, serving as the Director of Vascular Medicine at The Miriam Hospital and has led numerous trials in carotid stenting and endovascular procedures.

InspireMD's Growth: InspireMD, Inc. (NASDAQ:NSPR) has seen a 37.1% increase in institutional ownership by Parkman Healthcare Partners LLC, now holding nearly 3.82% of the company after acquiring 316,700 shares.

Company Developments: The Florida-based medical device company is enhancing its market position with new hires, including CFO Mike Lawless, and focuses on carotid artery treatments, while also being compared to AI stocks for investment potential.